JDD February 2026 Issue Highlights
Welcome to "JDD February 2026 Issue Highlights," your quick tour of this month’s Editor’s Picks from the Journal of Drugs in Dermatology, curated by the Next Steps in Derm Team. This issue pairs practical algorithms, novel therapeutics, real‑world effectiveness data, equity analyses, and procedural reports, all with immediate clinical relevance.
Explore this month’s top picks below:
…
Welcome to "JDD February 2026 Issue Highlights," your quick tour of this month’s Editor’s Picks from the Journal of Drugs in Dermatology, curated by the Next Steps in Derm Team. This issue pairs practical algorithms, novel therapeutics, real‑world effectiveness data, equity analyses, and procedural reports, all with immediate clinical relevance.
Explore this month’s top picks below:
… 
GLP-1 receptor agonists are revolutionizing the treatment of type 2 diabetes and obesity. With widespread consumer advertising campaigns, GLP-1 usage is becoming commonplace. National polls show up to one-fifth of American adults have tried GLP-1s for weight loss or to address health conditions, such as heart disease. As the understanding of GLP-1s deepens, so does their potential. Since recent re … 
Welcome to “JDD September 2025 Issue Highlights,” your guided tour through this month’s must-read studies, curated by the Journal of Drugs in Dermatology Editorial Team. This issue features a Special Focus on Aesthetic Treatments alongside cutting-edge research in novel pharmacotherapies, advanced procedural techniques, and safety assessments. Whether you’re dialing in volumization with po …